구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | KYV-101 (KYV-101, Biological, KYV-101 (Biological) - 0.33 ×10^8 cells) Kyverna Therapeutics·Progressive Multiple Sclerosis 133 trials |
|---|---|
Overview Program | KYV-101 (Biological) - 0.33 ×10^8 cells |
Overview Company | Kyverna Therapeutics |
Overview Modality | CGT |
Overview Target | Progressive Multiple Sclerosis |
Overview Indication | Progressive Multiple Sclerosis |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | , clinical efficacy, and safety of mosunetuzumab, an agent representative of immunotherapeutic advancement in lymphoma |
MoA Biomarker | EGFR2 gene expression |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.. To determine the prevalence of anti-drug antibodies (ADAs) in patients with psoriatic arthritis (PsA) treated with biological disease-modifying antirheumatic drugs (bDMARDs) and to evaluate associations with serum drug levels, clinical efficacy and safety. A Preferred Reporting Items for Systema… |
Clinical Safety signal | Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.. To determine the prevalence of anti-drug antibodies (ADAs) in patients with psoriatic arthritis (PsA) treated with biological disease-modifying antirheumatic drugs (bDMARDs) and to evaluate associations with serum drug levels, clinical efficacy and safety. A Preferred Reporting Items for Systema… |
Clinical Selected reported efficacy | 92.9% |
Clinical Result source | ClinicalTrials.gov NCT05966090 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT05966090 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | KYV-101 (KYV-101, Biological, KYV-101 (Biological) - 0.33 ×10^8 cells) Kyverna Therapeutics·Progressive Multiple Sclerosis 133 trials |
|---|---|
Overview Program | KYV-101 (Biological) - 0.33 ×10^8 cells |
Overview Company | Kyverna Therapeutics |
Overview Modality | CGT |
Overview Target | Progressive Multiple Sclerosis |
Overview Indication | Progressive Multiple Sclerosis |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | , clinical efficacy, and safety of mosunetuzumab, an agent representative of immunotherapeutic advancement in lymphoma |
MoA Biomarker | EGFR2 gene expression |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.. To determine the prevalence of anti-drug antibodies (ADAs) in patients with psoriatic arthritis (PsA) treated with biological disease-modifying antirheumatic drugs (bDMARDs) and to evaluate associations with serum drug levels, clinical efficacy and safety. A Preferred Reporting Items for Systema… |
Clinical Safety signal | Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.. To determine the prevalence of anti-drug antibodies (ADAs) in patients with psoriatic arthritis (PsA) treated with biological disease-modifying antirheumatic drugs (bDMARDs) and to evaluate associations with serum drug levels, clinical efficacy and safety. A Preferred Reporting Items for Systema… |
Clinical Selected reported efficacy | 92.9% |
Clinical Result source | ClinicalTrials.gov NCT05966090 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT05966090 |
추천 비교
추천 비교